Hexapeptide-11 vs Matrixyl
How Hexapeptide-11 and Matrixyl compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Hexapeptide-11 and Matrixyl come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Hexapeptide-11 vs Matrixyl, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Hexapeptide-11 | Matrixyl |
|---|---|---|
| What it is | Yeast-derived cosmetic hexapeptide (a six-amino-acid peptide originally isolated from yeast extract) | Synthetic lipopeptide (a 5-amino-acid collagen fragment, KTTKS, with a palmitic-acid tail) |
| Class / category | Cosmetic / skin | Cosmetic / skin |
| Evidence tier | In-vitro · Unclear · none in humans | Human (controlled) · Helped |
| Studied / approved for | Topical skin elasticity and firmness; Cellular senescence in cultured fibroblasts | Reducing the appearance of fine lines and wrinkles (topical); Supporting skin collagen and firmness (topical) |
| US regulatory status (2026) | unscheduled (as of Jul 2026) | unscheduled (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 0 |
| Banned in sport (WADA) | Unknown | Unknown |
| Key risks | Published safety evidence is thin. A 2015 paper found no significant toxicity in the fibroblast models it tested, but cell viability is not a human irritation, allergy, or long-term safety study. The same paper reported increased matrix metalloproteinase activity and slower fibroblast migration, findings whose practical meaning for normal topical use remains unknown. | Matrixyl is one of the better-tolerated cosmetic peptides. Used topically at the low concentrations found in leave-on serums and creams, it rarely causes more than occasional mild irritation, and it has a long track record as an over-the- counter skincare ingredient. It has not been studied for swallowing or injecting, and the "collagen-boosting" claim is stronger in a lab dish than on a face. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Hexapeptide-11 vs Matrixyl: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Matrixyl
Matrixyl's evidence sits at human (controlled), a more human tier than Hexapeptide-11's in-vitro. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Sklirou et al., 2015 — Hexapeptide-11 and the proteostasis network (PMID 25974626)
- 2.Gruber et al., 2013 — Modulation of cellular senescence in vitro (PMID 23578831)
- 3.Wu et al., 2021 — Cosmeceutical peptide mixtures in skin fibroblasts (PMID 33849044)
- 4.FDA — Does FDA approve cosmetics before they go on the market?
- 5.DailyMed — topical product label listing hexapeptide-11 as an inactive ingredient
- 6.USADA — Peptides and growth factors in cosmetics